Top Banner
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9 November 2006
42

The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Dec 14, 2015

Download

Documents

Megan Parks
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The Challenge from India

Dr. Brian W Tempest

Chief Mentor & Executive Vice Chairman of the Board

Ranbaxy Laboratories Limited, Delhi, India

Lisbon – 8/9 November 2006

Page 2: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Except for the historical information contained herein, statements in this presentation and

the subsequent discussions, which include words or phrases such as “will”, “aim”, “will

likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”,

“intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”,

“should”, “potential”, “will pursue” and similar expressions or variations of such

expressions may constitute "forward-looking statements". These forward-looking

statements involve a number of risks, uncertainties and other factors that could cause

actual results to differ materially from those suggested by the forward-looking statements.

These risks and uncertainties include, but are not limited to our ability to successfully

implement our strategy, our growth and expansion plans, obtain regulatory approvals, our

provisioning policies, technological changes, investment and business income, cash flow

projections, our exposure to market risks as well as other risks. Ranbaxy does not

undertake any obligation to update forward-looking statements to reflect events or

circumstances after the date thereof.

Disclaimer

Page 3: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Asia’s Share of the World GDP (at PPP in %)

Year 1870 1913 1950 1973 2001 China 17% 9% 5% 5% 12% India 12% 8% 4% 3% 5% Japan 2% 3% 3% 8% 7%

Rest of Asia 7% 5% 7% 9% 13% Total Asia 38% 25% 19% 25% 37%

Source – WEF

- was 59% in 1820 with India 16%, China 33%

Page 4: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

1. India +84%

2. Pakistan +75%

3. Korea +54%

4. Philippines +39%

5. China +34%

Stock Market Performance in Asia in 2005

Source: Rimes in GBP

Page 5: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Davos 2006

Source – FT

Page 6: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The Productivity Advantage

India a usa Pharma view USA India a usa Pharma view USA

1 chemist 1 chemist 1 chemist 1 chemist

70 hours/week 50 hours/week 70 hours/week 50 hours/week

$ 800 monthly $ 12,000 monthly $ 800 monthly $ 12,000 monthly

Better education x 1.3Better education x 1.3

Longer working time x 1.3Longer working time x 1.3

Lower cost x 20Lower cost x 20

Sources: IPHMR Conferences, New Delhi August 2004

Page 7: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Japan - by 2050 36% > 65 years from 19% in 2005

China - one child families, get older before becoming wealthy - labour costs will rise owing to labour shortage - South Guangdong province is short of 2m workers

India - will remain very young, 50% <25years, 65% <35 years - source of the extra needed global workforce

- in 2025 100m > 65 years (to China’s 200m)

The Ageing Advantage

Working Population, 15-64 yearsIn millions

Page 8: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Growth- Japan, sustain current growth- China, slightly slower growth to prevent hard landing

- India, increasing growth rate being talked up to 9%/10% Sentiment

- India, largest foreign affairs caucus in US Congress (180), nuclear deal - China, 74,000 demonstrations reported in 2005 in China. State secrecy, IP

The Economic Growth Advantage

Page 9: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The world has 793 billionaires USA has 371 – almost half India - 23 billionaires, UK has 24 China - 8 billionaires Net worth of 40 richest Indians - $106 b 40 richest Chinese - $26b

“2006 belongs to some of the emerging markets, and

no country more than India”

Source: Forbes

The Billionaires Advantage

Page 10: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The R&D Investment Advantage Most attractive R&D Investment locations:

1. China 2. USA 3. India 4. Japan 5. UK

Source – UNCTAD 2005

Page 11: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Qualified Scientists & Engineers

Global India players with Alliances

English speaking

TRIPs compliant – first patent March 2006

IIT, IIM & other scientific institutions

Source – UNCTAD 2005

The R&D Investment Advantage-reasons why India

Page 12: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

4th largest reservoir of Scientific Manpower (2nd largest English speaking)

3m graduates pa, 115k MSc Chemistry, 215k Eng (222k USA) Physics the most popular subject

Knowledge super power in the making

Lead by a Nuclear Scientist as President – remote sensing satellite technology, 1/6 countries

PCT application ranked 3rd – K, Ch, Ind, Si, RSA

Diaspora network (25m across 120 countries)

US & Europe will not dominate Science, Maths, IT

The Knowledge Advantage

Page 13: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Science Education in EU

“This means that when pupils are in a science laboratory their experience is unsafe, unsatisfactory or uninspiring for 65% of the time. In addition, 13% of science classes are not taught in a laboratory at all”

Source: Royal Society of Chemistry, Policy Bulletin – Spring 2006

UK “A” Level entries: Closed UK University 2000 2005 % change Chemistry Departments: Physics : 32,059 28,119 -12% Dundee Kings Chemistry: 40,856 38,851 -5% Surrey Exeter Maths: 67,036 52,897 -21% Lancaster Queen Mary Computing: 19,099 7,242 -62% under review-Sussex

Source: Daily Mail – 11 August 2006

Page 14: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Number of Higher Education Institutions

05/06 18,123 +59%

00/01 11,412

90/01 5,932

80/01 4,861

Source: Indian University Grants Commission

Science Education in India

Number of Students enrolled in

Higher Education Institutions

05/06 10,500 +40%

00/01 7,500

90/01 4,000

80/01 3,000Source: Indian University Grants Commission

Number of Institutions courses

05/06 99/00

Pharmacy 1478 669 +120%

Medicine 229 174 +32%

Physiotherapy 205 52 +294%

Source: Pavan Agarwal (2006) based on data

from professional councils

PhD Degree awarded in Science

03/04 5408 +44%

00/01 3734

90/01 2950

(USA 03/04 25,000)

Source: Indian University Grants Committee

Page 15: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The Knowledge Advantage

Engineers/Science graduates p.a – India 0.7m, China 0.5m, EU 0.5m, USA 0.4m, Japan 0.3m

Page 16: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

34 News TV channels. Oldest 13 years old (NDTV)

5000 newspapers, circulation 17m. 12 with 1m copies each.200m daily readers. 21m new daily readers 2003/2005, +14% with 50% rural and 50% urban readership

Principal internet languages to become English, Chinese and Hindi

Indians are hungry for information

The Information Advantage

Internet Usage – Asia

1. China 123 m2. Japan 86 m3. India

51 m4. S.Korea 34 m

Source: Business Today, Sept. 24, 2006

Mobile Phones

1. China 421 m2. USA

190 m3. Japan 157 m4. Russia 148 m5. India

116 m

Source: Times of India, Sept. 14, 2006

Page 17: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Manufacturing growth versus China Scope for improvement of Government Policies

Revitalization of agriculture - beyond milk (1st globally), wheat (2nd), rice (2rd)

More privatization – public sector not so buoyant

Further encouragement of R&D for Pharmaceuticals

Expand further the prosperous middle class of 300m

The Potential for Improvement Advantage

Page 18: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

CRO Market India

2006 $318 m +347%2005 $71 m2000 $10 m

Source:Clinivest Research Pvt. Ltd

Country USAIndia

Sites 22 8

Subject 626 896

Source: Andy Lee Pfizer Global, head clinical study and data management.Business India, August 13, 2006

“………..The Country’s World Class skills in Chemistry & IT and it’s large treatment naivepatient population provides added allure” Boston Consultancy Group

Harnessing the power of India 2006

The Clinical Advantage

Medical Tourism

Thailand India

- Open heart $14250 $4400

- Hysterectomy $ 2012 $ 571 - Knee surgery $7000 $4500

Patients

- Naïve- HIV 50m- Diabetes 32m- HT 5m

Page 19: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The M&A Future Advantage

Page 20: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

$b

1997/8 3.61998/9 2.51999/0 2.22000/1 4.02001/2 6.12002/3 5.02003/4 4.32004/5 5.62005/6 6.0

Source: Outlook business June 2006

- 2006/7 on target for $10b- But still only 15% of China

The FDI Advantage

Page 21: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

$m 2000 110 2001 160 2002 200 2003 250 2004 400 2005 450

- Leading to even more Pharma R&D facilities and factories

Source – Citigroup

Investment by top 15 Indian Domestic Pharmaceutical Companies

Page 22: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Investment by foreign Pharma companies

Page 23: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Microsoft Global Development Centre (GDCI)

Microsoft Global Services (MGSI)

Microsoft Global Technical Support Centre (GTSC)

Microsoft Systems Research (MSRI)

Microsoft India Development Centre (MIDC)

Investment by Microsoft in India

Page 24: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

A Global Strategic Asset for developed

World Market businesses

India

Page 25: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

$b 2004 2009

USA 15 27 W Europe 9 14 Japan 3 4 Rest of America 6 9 ROW 25 40

Total 58 94 Source: Frost & Sullivan

“India could soon dominate the entire production chain for generics”

IMS prediction No 4 Scrip April 5 2006

The Global Generic Market – growing everywhere

Page 26: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The Pharma Advantage

Competitive Advantage – Aggressive Home Market

Page 27: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The Pharma Advantage

Competitive Advantage - Cost of Manufacture

Active Pharmaceuticals Facility, Mohali Dosage Forms Facility, Paonta Sahib

Highest number of FDA approved plants outside the USNo. of FDA approved plants:

1990 11995 102000 442004 105

Source: Crisil / IPA

Page 28: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.
Page 29: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The Pharma Advantage

R&D I

R&D III

R&D II

Competitive Advantage - Cost of Innovation

Ranbaxy’s Patent Filings

2449

32

86

146

24

170

185

2001

2000

1999

20042005

Page 30: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

The Pharma Advantage – API’s

USA DMF filings by India

1990 1 1995 4 2000 36

2004 187 2005 262

Source: Crisil / US FDA / J P Morgan

% Share of USA DMF filings

India China 2004 27% 9% 2005 37% 10% Q1’06 44% 15% Q2’06 41% 16%

Source: US FDA / J P Morgan 6th August 2006

Page 31: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Annual USA ANDA FilingsRanbaxy 29Sun 22Orchid 18Lupin 14DRL 13Cadilla 12

Source: Pharmabiz 8th Sept’ 2005

- One in every four ANDAs filed by Indian Companies in top USA FDA filers Source: KPMG

- 29 ANDAs p.a ranks in top 3 USA FDA filers

- Indian Generic Companies on a Filing Spree - BOA

- - No Chinese generic company has yet filed a USA FDA - ANDA

The Pharma Advantage - ANDAs

Page 32: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

0

1000

2000

3000

4000

5000

6000

7000

8000

9000

0

1000

2000

3000

4000

5000

6000

7000

8000

9000

Leading Generic Companies

Source : Company /Financial reports & presentations

Annual Sales (US$ Millions)

Source: CLSA, 6 August 2006

Page 33: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

A race to Prosperity in Asia

•With Law (India) & Order (China)

•Buddhism

•Joint Bids for oil assets

•Silk road re-opened – Sikkim to Tibet (Nathula Pass)

•Calcutta port is only 1120k from Lhasa

•India leading in the Pharma race

Page 34: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Potential Downsides to theIndian Scenario

Page 35: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Potential downside – Asian Flu*

*50% of world chickens bred in Asia

Page 36: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Potential downside – Oil prices

Source – Outlook business June 2006

• A war against Iran could drive oil > $200 a barrel - ‘Times’ 22nd June 2006• Oil is 33% of Indian Energy Sources – IMA, India June 2006• BRIC countries consume 20% oil

Source – EIIG Source – BP

Page 37: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

USA – 4% population with 20% emissions

China – Same level as USA in 2005. In 2025 will be double

India, China, USA – Refuse any mandatory CO2 emission caps

India is 6th greatest energy consumer

Ganges River is the World’s most polluted river

– source: World Commission on water

Potential Downside - Pollution

Page 38: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Potential downside – InfrastructureA common view

Source – Manmohan Singh

- Infrastructure will need $155b over the next five years

Page 39: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Potential downside – Counterfeit products from India-but not a global issue

Origin of fake products

seized in EU in 2004

Rank

1. China

2. Thailand

3. Hong Kong

4. Turkey

5. USA

Source: FT

Countries where fake

pharma products seized in

2005Rank

1. Russia

2. China

3. South Korea

4. Peru

5. Columbia

Source: PSI

192,000 died from Counterfeit drugs in China in 2001 Source: IMS 27th Feb’2006

Page 40: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Asia economic strength is returning to levels seen in the past

Many advantages for India – R&D, Demographics education India as a global strategic asset Some downsides - infrastructure

The current feeling in India a turning point has been reached and an inflexion point has been passed

“China & India represent the future of Asia and quite possiblythe future for the global economy” – Steve Roach, Morgan Stanley

Summary

Page 41: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

“We have all grown up learning the story of the unfinished voyage of Christopher Columbus

setting sail to reach India, he discovered America. I now invite the people of America to complete the

Voyage of that great explorer”

Manmohan SinghPrime Minister of India

July 2005

Page 42: The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Lisbon – 8/9.

Thank You